Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Оценка данных вариации литературных источников для определения объема выборки клинических исследований биоэквивалентности
Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Галерея

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants
Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-12-02
Pharmacy Compounding Advisory Committee Roster
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-02 By FDA
Biosimilar Product Information
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA
Global Generic Drug Affairs
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA
FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA
Human medicines European public assessment report (EPAR): Xofluza, baloxavir marboxil, Date of authorisation: 07/01/2021, Revision: 8, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Rasagiline Viatris (previously Rasagiline Mylan), rasagiline, Date of authorisation: 04/04/2016, Revision: 11, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Adynovi, rurioctocog alfa pegol, Date of authorisation: 08/01/2018, Revision: 15, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 28, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Date of authorisation: 21/03/2007, Revision: 42, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Cerezyme, imiglucerase, Date of authorisation: 17/11/1997, Revision: 34, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Human medicines European public assessment report (EPAR): Erleada, apalutamide, Date of authorisation: 14/01/2019, Revision: 19, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-01
Patient-Focused Drug Development
Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-01 By FDA

Older posts

Тема: Scaffold от Danny Cooper.